参考文献/References:
[1] Franks S. Polycystic ovary syndrome[J].N Engl J Med,1995,333(13):853-861.
[2] Johnson T, Kaplan L, Ouyang P, et al. Evidence-based methodology workshop on polycystic
ovary syndrome. http://prevention.nih.gov/docs/programs/pcos/Final Report.pdf. Maryland:
National Institutes of Health, 2012.
[3] Zawadzki JK. Diagnostic criteria for polycystic ovary syndrome: towards a rational
approach. Dunaif A,eds.Polycystic ovary syndrome[M].Boston: Blackwell Scientific,1995:377-384.
[4] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on
diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS)[J].Hum
Reprod,2004,19(1):41-47.
[5] Azziz R, Carmina E, Dewailly D,et al. Positions statement: criteria for defining polycystic
ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society
guideline[J].J Clin Endocrinol Metab,2006,91(11):4237-4245.
[6] Nader S. Hyperandrogenism during puberty in the development of polycystic ovary syndrome
[J].Fertil Steril,2013,100(1):39-42. DOI: 10.1016/j.fertnstert.2013.03.013.
[7] Merino PM, Codner E, Cassorla F. A rational approach to the diagnosis of polycystic ovarian
syndrome during adolescence[J].Arq Bras Endocrinol Metabol,2011,55(8):590-598.
[8] Rosenfield RL. Clinical review: Adolescent anovulation: maturational mechanisms and
implications[J].J Clin Endocrinol Metab,2013,98(9):3572-3583. DOI: 10.1210/jc.2013-1770.
[9] Ibánez L, Ong KK, López-Bermejo A, et al. Hyperinsulinaemic androgen excess in
adolescent girls[J].Nat Rev Endocrinol,2014,10(8):499-508. DOI: 10.1038/nrendo.2014.58.
[10] Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's
health aspects of polycystic ovary syndrome(PCOS)[J]. Hum Reprod,2012,27(1):14-24. DOI:
10.1093/humrep/der396.
[11] Legro RS, Arslanian SA, Ehrmann DA,et al. Diagnosis and treatment of polycystic ovary
syndrome: an Endocrine Society clinical practice guideline[J].J Clin Endocrinol Metab,2013,98
(12):4565-4592. DOI: 10.1210/jc.2013-2350.
[12] Flannery CA, Rackow B, Cong X,et al. Polycystic ovary syndrome in adolescence: impaired
glucose tolerance occurs across the spectrum of BMI[J].Pediatr Diabetes,2013,14(1):42-49. DOI:
10.1111/j.1399-5448.2012.00902.x.
[13] Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary
syndrome[J]. Cochrane Database Syst Rev, 2011(7):Cd007506. DOI: 10.1002/14651858.CD007506.pub3.
[14] Lass N, Kleber M, Winkel K,et al. Effect of lifestyle intervention on features of
polycystic ovarian syndrome, metabolic syndrome, and intima-media thickness in obese adolescent
girls[J].J Clin Endocrinol Metab,2011,96(11):3533-3540. DOI: 10.1210/jc.2011-1609.
[15] Abazar E, Taghian F, Mardanian F, et al. Effects of aerobic exercise on plasma lipoproteins
in overweight and obese women with polycystic ovary syndrome[J].Adv Biomed Res,2015,4:68. DOI:
10.4103/2277-9175.153892.
[16] Kiddy DS, Hamilton-Fairley D, Bush A,et al. Improvement in endocrine and ovarian function
during dietary treatment of obese women with polycystic ovary syndrome[J].Clin Endocrinol(Oxf),
1992,36(1):105-111.
[17] Ornstein RM, Copperman NM, Jacobson MS. Effect of weight loss on menstrual function in
adolescents with polycystic ovary syndrome[J].J Pediatr Adolesc Gynecol,2011,24(3):161-165. DOI:
10.1016/j.jpag.2011.01.002.
[18] Hoeger K, Davidson K, Kochman L, et al. The impact of metformin, oral contraceptives, and
lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized,
placebo-controlled clinical trials[J].J Clin Endocrinol Metab,2008,93(11):4299-4306. DOI:
10.1210/jc.2008-0461.
[19] Vitek W, Hoeger KM. Treatment of polycystic ovary syndrome in adolescence[J].Semin Reprod
Med,2014,32(3):214-221. DOI: 10.1055/s-0034-1371093.
[20] Mathur R, Levin O, Azziz R. Use of ethinylestradiol/drospirenone combination in patients
with the polycystic ovary syndrome[J].Ther Clin Risk Manag,2008,4(2):487-492.
[21] Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the
treatment of women with polycystic ovary syndrome[J]. Eur J Contracept Reprod Health
Care,2007,12(1):30-35.
[22] Guido M, Romualdi D, Giuliani M,et al. Drospirenone for the treatment of hirsute women with
polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study[J].J Clin
Endocrinol Metab,2004,89(6):2817-2823.
[23] Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and
finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-
controlled trial[J].J Clin Endocrinol Metab,2000,85(1):89-94.
[24] Castelo-Branco C, Del Pino M. Hepatotoxicity during low-dose flutamide treatment for
hirsutism[J].Gynecol Endocrinol, 2009,25(7):419-422.
[25] Fauser BC, Tarlatzis BC, Rebar RW,et al. Consensus on women's health aspects of polycystic
ovary syndrome(PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group
[J].Fertil Steril,2012,97(1):28-38.e25. DOI: 10.1016/j.fertnstert.2011.09.024.
[26] Glintborg D, Altinok ML, Mumm H, et al. Body composition is improved during 12 months'
treatment with metformin alone or combined with oral contraceptives compared with treatment with
oral contraceptives in polycystic ovary syndrome[J].J Clin Endocrinol Metab,2014,99(7):2584-
2591. DOI: 10.1210/jc.2014-1135.
[27] Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management
of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome
Society[J].Hum Reprod Update,2012,18(2):146-170.DOI: 10.1093/humupd/dmr042.
[28] Ganie MA, Khurana ML, Nisar S,et al. Improved efficacy of low-dose spironolactone and
metformin combination than either drug alone in the management of women with polycystic ovary
syndrome(PCOS): a six-month, open-label randomized study[J].J Clin Endocrinol Metab,2013,98
(9):3599-3607. DOI: 10.1210/jc.2013-1040.
[29] Ibáñez L, Valls C, Ferrer A, et al. Additive effects of insulin-sensitizing and anti-
androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism,
dyslipidemia, and anovulation[J].J Clin Endocrinol Metab,2002,87(6):2870-2874.
[30] Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, et al. The polycystic ovary
syndrome associated with morbid obesity may resolve after weight loss induced by bariatric
surgery[J].J Clin Endocrinol Metab,2005,90(12):6364-6369.
[31] Eid GM, Cottam DR, Velcu LM, et al. Effective treatment of polycystic ovarian syndrome with
Roux-en-Y gastric bypass[J].Surg Obes Relat Dis,2005,1(2):77-80.
相似文献/References:
[1]高四书 王龙 华飞.晚期糖基化终末产物与多囊卵巢综合征的关系[J].国际内分泌代谢杂志,2018,38(04):279.[doi:10.3760/cma.j.issn.1673-4157.2018.04.015]
Gao Sishu,Wang Long,Hua Fei.Relationship between advanced glycation end-products and polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2018,38(05):279.[doi:10.3760/cma.j.issn.1673-4157.2018.04.015]
[2]叶凌霞 洪洁.多囊卵巢综合征与肠道菌群[J].国际内分泌代谢杂志,2019,39(05):345.[doi:10.3760/cma.j.issn.1673-4157.2019.05.014]
Ye Lingxia,Hong Jie.Polycystic ovary syndrome and gut microbiota[J].International Journal of Endocrinology and Metabolism,2019,39(05):345.[doi:10.3760/cma.j.issn.1673-4157.2019.05.014]
[3]牟靖 谈宗国 吴萍.miRNA-320及其靶基因内皮素-1与多囊卵巢
综合征易感性及临床特点的关系研究[J].国际内分泌代谢杂志,2020,40(02):87.[doi:10.3760/cma.j.issn.1673-4157.2020.02.004]
Mou Jing,Tan Zongguo,Wu Ping.Relationship between miRNA-320, its target gene endothelin-1 and the susceptibility and clinical features of polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2020,40(05):87.[doi:10.3760/cma.j.issn.1673-4157.2020.02.004]
[4]蔡美丽,张曼娜,曲伸.代谢手术对肥胖女性生殖内分泌系统疾病影响的研究进展[J].国际内分泌代谢杂志,2023,43(06):469.[doi:10.3760/cma.j.cn121383-20230830-08071]
Cai Meili,Zhang Manna,Qu Shen..Research progress on the impact of metabolic surgery on reproductive endocrine system diseases in obese women[J].International Journal of Endocrinology and Metabolism,2023,43(05):469.[doi:10.3760/cma.j.cn121383-20230830-08071]